| Market Cap | 485.26M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -33.52M | Forward P/E | -8.50 | EPS next Y | -26.70% | 50D Avg Chg | -1.00% |
| Sales | 264.78M | PEG | -0.11 | EPS past 5Y | 65.15% | 200D Avg Chg | -15.00% |
| Dividend | N/A | Price/Book | 0.85 | EPS next 5Y | 38.90% | 52W High Chg | -47.00% |
| Recommedations | 3.70 | Quick Ratio | 1.87 | Shares Outstanding | 411.17M | 52W Low Chg | 14.00% |
| Insider Own | 1.59% | ROA | -2.02% | Shares Float | 383.41M | Beta | 1.93 |
| Inst Own | 19.77% | ROE | -5.98% | Shares Shorted/Prior | 18.23M/18.61M | Price | 1.19 |
| Gross Margin | 61.29% | Profit Margin | -12.66% | Avg. Volume | 2,478,600 | Target Price | 1.00 |
| Oper. Margin | -0.78% | Earnings Date | Oct 30 | Volume | 2,150,082 | Change | 0.00% |
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
| Cantor Fitzgerald | Overweight | Jun 20, 24 |
| Cantor Fitzgerald | Overweight | Jun 18, 24 |
| Jefferies | Hold | Oct 25, 23 |
| Goldman Sachs | Sell | Jul 20, 23 |
| Northland Capital Markets | Market Perform | Jul 19, 23 |
| Jefferies | Buy | Jan 6, 23 |
| SVB Leerink | Market Perform | Oct 19, 22 |
| Goldman Sachs | Sell | May 24, 22 |
| JP Morgan | Underweight | May 6, 22 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Ketchum Steven B | Chief Scientific Off.. Chief Scientific Officer | Dec 12 | Sell | 0.79 | 34,131 | 26,963 | 566,100 | 12/14/23 |
| Holt Patrick | President and CEO President and CEO | Aug 16 | Buy | 1.04 | 300,000 | 312,000 | 300,000 | 08/16/23 |
| WOLD OLSEN PER | Director Director | Jun 13 | Buy | 1.686 | 55,000 | 92,730 | 149,000 | 06/15/22 |
| STACK DAVID M | Director Director | Jun 07 | Buy | 4.58 | 15,000 | 68,700 | 40,000 | 06/07/21 |
| Ketchum Steven B | Chief Scientific Off.. Chief Scientific Officer | Feb 03 | Option | 2.65 | 192,358 | 509,749 | 600,724 | 02/03/21 |
| Ketchum Steven B | Chief Scientific Off.. Chief Scientific Officer | Feb 03 | Sell | 8.04 | 217,728 | 1,750,533 | 382,996 | 02/03/21 |
| Ketchum Steven B | Chief Scientific Off.. Chief Scientific Officer | Jan 29 | Option | 2.4 | 278,237 | 667,769 | 809,741 | 01/29/21 |
| Ketchum Steven B | Chief Scientific Off.. Chief Scientific Officer | Jan 29 | Sell | 8.01 | 421,629 | 3,377,248 | 388,112 | 01/29/21 |
| THERO JOHN F | President and CEO President and CEO | Nov 12 | Option | 3.4 | 750,000 | 2,550,000 | 3,306,405 | 11/12/20 |
| THERO JOHN F | President and CEO President and CEO | Nov 12 | Sell | 4.1 | 567,405 | 2,326,360 | 2,739,000 | 11/12/20 |